Free Trial
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

$197.04
-11.30 (-5.42%)
(As of 07/26/2024 ET)
Today's Range
$196.43
$207.04
50-Day Range
$182.36
$218.85
52-Week Range
$132.24
$229.97
Volume
1.86 million shs
Average Volume
1.05 million shs
Market Capitalization
$28.95 billion
P/E Ratio
30.27
Dividend Yield
0.97%
Price Target
$203.20

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.55 Rating Score
Upside/​Downside
3.1% Upside
$203.20 Price Target
Short Interest
Bearish
5.77% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.60mentions of ResMed in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$9.69 M Sold Last Quarter
Proj. Earnings Growth
13.25%
From $7.70 to $8.72 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.22 out of 5 stars

Medical Sector

165th out of 936 stocks

Surgical & Medical Instruments Industry

24th out of 101 stocks

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
Behind the Scenes of ResMed's Latest Options Trends
ResMed (NYSE:RMD) Price Target Raised to $204.00
Analysts Set ResMed Inc. (NYSE:RMD) PT at $202.80
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Ex-Dividend for 6/13 Dividend
5/08/2024
Dividend Payable
6/13/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/01/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
10,140
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$203.20
High Stock Price Target
$238.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+2.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
11 Analysts

Profitability

Net Income
$897.56 million
Pretax Margin
25.83%

Debt

Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.54 per share
Book Value
$28.11 per share

Miscellaneous

Free Float
145,129,000
Market Cap
$29.25 billion
Optionable
Optionable
Beta
0.66

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed's recent increase in target price by KeyCorp and Royal Bank of Canada indicates positive sentiment from analysts, potentially leading to stock price appreciation.
  • ResMed's consistent dividend payments, with a recent quarterly dividend of $0.48 per share, providing investors with a steady income stream.
  • Insiders owning 1.21% of the company's stock can signal confidence in the company's future performance, aligning their interests with shareholders.
  • ResMed's focus on developing medical devices and cloud-based software applications for healthcare markets positions the company well in a growing industry with long-term demand.
  • Recent insider selling activity may not necessarily be a negative signal, as it could be part of a planned selling strategy or profit-taking by insiders.

Cons

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • The recent downgrade by Oppenheimer and Citigroup from "outperform" and "buy" ratings to "market perform" and "neutral" ratings respectively may indicate potential challenges or concerns in the company's performance.
  • ResMed's stock price volatility, influenced by market conditions and industry competition, may lead to fluctuations in investment returns.
  • While insider ownership can be positive, high levels of insider selling, such as the recent 31,151 shares sold, could raise questions about insider confidence or future prospects.
  • ResMed's payout ratio of 29.49% indicates that a significant portion of the company's earnings is being distributed as dividends, potentially limiting reinvestment for growth.
  • Analysts' mixed ratings on the stock, with six hold ratings and six buy ratings, may create uncertainty among investors regarding the company's future performance and stock price movement.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 5, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

RMD Stock Analysis - Frequently Asked Questions

How have RMD shares performed this year?

ResMed's stock was trading at $172.02 at the beginning of 2024. Since then, RMD shares have increased by 14.5% and is now trading at $197.04.
View the best growth stocks for 2024 here
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its earnings results on Thursday, April, 25th. The medical equipment provider reported $2.13 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.22. The firm's revenue for the quarter was up 7.2% on a year-over-year basis.
Read the conference call transcript
.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does ResMed have any subsidiaries?

ResMed subsidiaries include Propeller Health, and Matrixcare.

Who are ResMed's major shareholders?

Top institutional investors of ResMed include Bank of New York Mellon Corp (3.93%), LGT Capital Partners LTD. (0.38%), Sumitomo Mitsui Trust Holdings Inc. (0.23%) and New York State Teachers Retirement System (0.09%). Insiders that own company stock include Michael J Farrell, Robert Andrew Douglas, Peter C Farrell, Brett Sandercock, David Pendarvis, Justin Leong, Kaushik Ghoshal, Karen Drexler, Witte Jan De, Lucile Blaise, Michael J Rider, Carol Burt and James Hollingshead.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE) and Visa (V).

This page (NYSE:RMD) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners